Study 10 of 15Cagrilintide (AM833) literatureThe lancet. Diabetes & endocrinologyTop journal2026
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
Not reported in abstract.
Where it sits
this study against the rest of the cagrilintide (am833) corpus3
Preclinical · this one
3
Observational
0
Open-label
3
Randomised
6
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Cagrilintide (AM833) corpus
AAmylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026 · n=5425 · -6.08% body weight, -5.89 kg with Cagrilintide monotherapyreviewDBeyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs.Pharmacological research · 2026reviewAEfficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.The lancet. Gastroenterology & hepatology · 2023 · n=698 · 24 [24%] of 99 participants in the zalfermin 30 mg plus semaglutide 2·4 mg group improved in liver fibrosis vs 16 [16%] of 100 participants in the placebo group; p=0·19.HumanCDistinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.Nature metabolism · 2023 · Not reported in abstract.AnimalAEfficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes, obesity & metabolism · 2023 · 30.3% achieved BMI < 27 kg/m² and WHtR < 0.53 with CagriSema at week 68.HumanACagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2024 · n=2713 · Mean HbA1c change was significantly greater with cagrilintide-semaglutide (2.4 mg each) versus semaglutide 2.4 mg (-1.91 percentage points vs -1.75 percentage points; p=0.0035).Human